Targeted therapy has already achieved great progress in many kinds of cancers included CRC, the monoclonal antibody (MoAb) cetuximab or panitumumab which targeted on epidermal growth factor receptor (EGFR) prolonged survival of metastatic CRC (mCRC) patients5, although only selected groups may benefit from these agents. The gene discussed is EGFR; the disease is cancer.